Tegafur,Gimeracil and Oteracil Potassium

Generic Name: Tegafur,Gimeracil and Oteracil Potassium

Indication: 用于不能切除的局部晚期或转移性胃癌。

用于治疗成人胆道癌【日本PMDA已批准；《胆管癌诊断与治疗-外科专家共识》】。

Clinical Trials

A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

Phase 2

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Donafenib
Drug: S1

First Posted Date: 2021-11-30

Last Posted Date: 2021-11-30

Lead Sponsor: Fudan University

Target Recruit Count: 10

Registration Number: NCT05138159

Locations: 🇨🇳
Fudan University, Shanghai, China

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Phase 2

Conditions: Gastric Neoplasms
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Camrelizumab
Drug: Pyrotinib
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Paclitaxel
Drug: S-1

First Posted Date: 2021-11-08

Last Posted Date: 2021-11-08

Lead Sponsor: Fudan University

Target Recruit Count: 65

Registration Number: NCT05111444

Locations: 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

Phase 2

Active, not recruiting

Conditions: Phase II, Open-label, Parallel 2-arm, Multi-center

Interventions: Drug: Gemcitabine 1000 mg
Drug: Nab paclitaxel
Drug: S1
Drug: Oxaliplatin
Drug: leucovorin

First Posted Date: 2021-08-30

Last Posted Date: 2025-05-07

Lead Sponsor: National Health Research Institutes, Taiwan

Target Recruit Count: 66

Registration Number: NCT05026905

Locations: 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan

and more 1 locations

Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer

Phase 2

Conditions: Perioperative
Sintilimab
Gastric Cancer

Interventions: Drug: Sintilimab
Drug: Oxaliplatin
Drug: S-1

First Posted Date: 2021-07-29

Last Posted Date: 2021-08-31

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 210

Registration Number: NCT04982939

Locations: 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach

Phase 2

Withdrawn

Conditions: Gastric Cancer

Interventions: Drug: Apatinib
Drug: Oxaliplatin
Drug: S1

First Posted Date: 2021-04-28

Last Posted Date: 2025-02-21

Lead Sponsor: Peking University

Target Recruit Count: 41

Registration Number: NCT04863430

Locations: 🇨🇳
Beijing Cancer Hospital / Peking University Cancer Hospital, Beijing, Beijing, China

A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection

Recruiting

Conditions: Recurrence
Cholangiocarcinoma
Gall Bladder Cancer
Biliary Tract Neoplasms

Interventions: Drug: Capecitabine
Drug: S-1

First Posted Date: 2021-04-23

Last Posted Date: 2022-08-18

Lead Sponsor: Fudan University

Target Recruit Count: 160

Registration Number: NCT04856761

Locations: 🇨🇳
Huashan hospital, Shanghai, China

Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC

Phase 2

Recruiting

Conditions: Stomach Cancer

Interventions: Drug: Tirelizumab
Drug: Trastuzumab
Drug: Docetaxel
Drug: S1
Drug: Oxaliplatin

First Posted Date: 2021-03-29

Last Posted Date: 2023-04-25

Lead Sponsor: The First Affiliated Hospital of Zhengzhou University

Target Recruit Count: 67

Registration Number: NCT04819971

Locations: 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Phase 2

Recruiting

Conditions: Metastatic Gastroesophageal Junction Adenocarcinoma
Metastatic Gastric Adenocarcinoma

Interventions: Drug: Camrelizumab
Drug: Apatinib Mesylate
Drug: S1
Drug: Docetaxel injection

First Posted Date: 2021-03-04

Last Posted Date: 2021-05-17

Lead Sponsor: Zhou Fuxiang

Target Recruit Count: 35

Registration Number: NCT04781686

Locations: 🇨🇳
Zhongnan Hopital of Wuhan University, Wuhan, Hubei, China

The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

Phase 2

Completed

Conditions: Stomach Neoplasms

Interventions: Drug: Camrelizumab
Drug: S-1
Drug: Oxaliplatin
Drug: Paclitaxel

First Posted Date: 2021-01-05

Last Posted Date: 2024-02-07

Lead Sponsor: Quan Wang

Target Recruit Count: 37

Registration Number: NCT04694183

Locations: 🇨🇳
First Hospital of Jilin University, Changchun, Jilin, China

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Phase 2

Recruiting

Conditions: Pan-tumor

Interventions: Drug: ONO-4538
Drug: oxaliplatin
Drug: S-1
Drug: capecitabine
Drug: bevacizumab
Drug: temozolomide

First Posted Date: 2020-09-28

Last Posted Date: 2024-05-03

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 59

Registration Number: NCT04566380

Locations: 🇯🇵
Kanagawa Clinical Site1, Yokohama, Kanagawa, Japan
🇯🇵
Tokyo Clinical Site3, Bunkyo-ku, Tokyo, Japan
🇯🇵
Chiba Clinical Site2, Chiba, Japan

and more 35 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy